Screening anlotinib responders via blood‐based proteomics in non‐small cell lung cancer-Reference-Cited by-同舟云学术

Screening anlotinib responders via blood‐based proteomics in non‐small cell lung cancer

Published:2022-07-22 Issue:8 Volume:36 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:The FASEB Journal

Author:

Lu Jun¹²³⁴,Zhang Wei¹,Yu Keke⁴,Zhang Lele¹,Lou Yuqing¹,Gu Ping¹,Nie Wei¹,Qian Jie⁵,Xu Jun⁶,Wang Huimin¹,Zhong Hua¹,Han Baohui¹²³^ORCID

Affiliation:

1. Department of Pulmonary Medicine Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

2. Shanghai Institute of Thoracic Oncology Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

3. Translational Medical Research Platform for Thoracic Oncology Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

4. Department of Bio‐Bank Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

5. Department of Emergency Medicine Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

6. Department of Emergency Medicine The First Hospital of Anhui Medical University Hefei China

Funder

Chinese Society of Clinical Oncology

Shanghai Chest Hospital

Shanghai Jiao Tong University

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202101658R

Reference37 articles.

1. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

2. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

3. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)

4. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

5. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosomal Proteomics: Unveiling Novel Insights into Lung Cancer;aging and disease;2024

2. PEG2000-PLA-based nanoscale polymeric micelles reduce paclitaxel-related toxicity in beagle dogs;Journal of Controlled Release;2023-10

3. Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells;Hematology;2023-08-18

4. Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery;International Journal of Nanomedicine;2023-01

5. Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis;BioMed Research International;2022-12-15